Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Diversified Trust Co

Diversified Trust Co raised its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,639 shares of the medical research company’s stock after buying an additional 708 shares during the quarter. Diversified Trust Co’s holdings in Exact Sciences were worth $710,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Huntington National Bank increased its position in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of Exact Sciences during the third quarter worth about $34,000. Capital Performance Advisors LLP purchased a new position in shares of Exact Sciences during the third quarter valued at approximately $35,000. Vestor Capital LLC acquired a new stake in Exact Sciences during the third quarter worth approximately $46,000. Finally, V Square Quantitative Management LLC purchased a new stake in Exact Sciences in the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Down 0.7 %

Shares of NASDAQ:EXAS opened at $56.68 on Friday. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of -48.44 and a beta of 1.24. The company has a 50 day moving average of $58.09 and a two-hundred day moving average of $58.56. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, analysts forecast that Exact Sciences Co. will post -1.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Jefferies Financial Group lifted their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Citigroup lowered their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Stifel Nicolaus cut their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Benchmark lowered their target price on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Craig Hallum decreased their price target on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.94.

Insider Activity

In related news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.36% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.